Bacillus atrophaeus inactivated spores as a potential adjuvant for veterinary rabies vaccine

Vaccine

Volumn 30, Issue 23, 2012, Pages 3351-3354

  Oliveira Nascimento, L ^a   Caricati, A T P ^a,b   Abdulack Lopes, F ^a   Neves, L C M ^a   Caricati, C P ^b   Penna, T C V ^a   Stephano, M A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

Author keywords

Adjuvant; Bacillus atrophaeus; Rabies; Saponin; Vaccine

Indexed keywords

IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; RABIES VACCINE; SAPONIN;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BACILLUS; BACILLUS ATROPHAEUS; BACTERIAL SPORE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG FORMULATION; DRUG POTENCY; DRUG STABILITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABIES; VIRUS TITRATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; BACILLUS; DRUG STABILITY; MICE; RABIES VACCINES; SPORES, BACTERIAL; VACCINES, INACTIVATED; VETERINARY MEDICINE;

EID: 84859823603     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.029     Document Type: Article

References (17)

1. Anon Compendium of animal rabies prevention and control, 2011. MMWR Recomm Rep 2011, 60(RR-6):1-17.
2. Anon Rabies vaccines: WHO position paper-recommendations. Vaccine 2010, 28(44):7140-7142.
3. Jackson A.C. Therapy of human rabies. Adv Virus Res 2011, 79:365-375.
4. Rajput Z.I., Hu S., Xiao C., Arijo A.G. Adjuvant effects of saponins on animal immune responses. J Zhejiang Univ Sci B 2007, 8(3):153-161.
5. Stephano M.A., Caricati C.P., Almeida P.G., Guidolin R., Higashi H.G. Safety in the use of saponins (QSA®) as an adjuvant in veterinary vaccines. New diagnostic technology: applications in animal health and biologics controls: international conference, 1st ed. 2006, 102.
6. Ren J., Sun L., Yang L., Wang H., Wan M., Zhang P., et al. A novel canine favored CpG oligodeoxynucleotide capable of enhancing the efficacy of an inactivated aluminum-adjuvanted rabies vaccine of dog use. Vaccine 2010, 28(12):2458-2464.
7. Morein B., Hu K-F., Abusugra I. Current status and potential application of ISCOMs in veterinary medicine. Adv Drug Deliv Rev 2004, 56(10):1367-1382.
8. Fritze D., Pukall R. Reclassification of bioindicator strains Bacillus subtilis DSM 675 and Bacillus subtilis DSM 2277 as Bacillus atrophaeus. Int J Syst Evol Microbiol 2001, 51(Pt. 1):35-37.
9. Barnes A.G.C., Cerovic V., Hobson P.S., Klavinskis L.S. Bacillus subtilis spores: a novel microparticle adjuvant which can instruct a balanced Th1 and Th2 immune response to specific antigen. Eur J Immunol 2007, 37(6):1538-1547.
10. Huang J-M., Hong H.A., Van Tong H., Hoang T.H., Brisson A., Cutting S.M. Mucosal delivery of antigens using adsorption to bacterial spores. Vaccine 2010, 28(4):1021-1030.
11. Penna T.C.V., Marques M., Machoshvili I.A., Ishii M. The effect of composition of parenteral solution on the thermal resistance of Bacillus stearothermophilus and Bacillus subtilis spores. Appl Biochem Biotechnol 2002, 98-100:539-551.
12. de Moura W.C., Gallina N.M.F., Fuches R.M.M., Romijn P.C., Leite J.P.G. Validation of a virus neutralization potency test in BHK-21 cells for rabies immunoglobulins in a two-center study. J Virol Methods 2008, 154(1-2):7-13.
13. Barth R., Groß-Albenhausen E., Jaeger O., Milcke L. The antibody-binding-test, a useful method for quantitative determination of inactivated rabies virus antigen. J Biol Stand 1981, 9(1):81-89.
14. Reed L.J., Muench H. A simple method of estimating fifty per cent end points. Am J Epidemiol 1938, 27(3):493-497.
15. Feyssaguet M., Dacheux L., Audry L., Compoint A., Morize J.L., Blanchard I., et al. Multicenter comparative study of a new ELISA, PLATELIA(TM) RABIES II, for the detection and titration of anti-rabies glycoprotein antibodies and comparison with the rapid fluorescent focus inhibition test (RFFIT) on human samples from vaccinated and non-vaccinated people. Vaccine 2007, 25(12):2244-2251.
16. Council of Europe Rabies vaccine (inactivated) for veterinary use. European pharmacopoeia 2005, Strasbourg, Council of Europe, p. 790-2. 5th ed.
17. Dobbelaer R., Pfleiderer M., Haase M., Griffiths E., Knezevic I., Merkle A., et al. Guidelines on stability evaluation of vaccines. Biologicals 2009, 37(6):424-434. [discussion 421-3].